Efficacy of the partricin derivative SPA-S-753 against systemic murine candidosis

J Antimicrob Chemother. 2001 Feb;47(2):183-6. doi: 10.1093/jac/47.2.183.


The polyene partricin compound SPA-S-753 (Societa Prodotti Antibiotici, Milano, Italy) was assessed in a murine model of systemic candidosis. CD-1 mice were infected iv with Candida albicans and treated iv with SPA-S-753 or amphotericin B. All treatment regimens of SPA-S-753 or amphotericin B were equivalent and significantly prolonged survival compared with controls (P < 0.001). Amphotericin B and SPA-S-753 significantly reduced burdens of C. albicans in the spleen and kidneys. Overall, cure rates were similar, amphotericin B at 1 mg/kg cured three and SPA-S-753 at 10 mg/kg cured four mice of infection in both organs. The efficacy of SPA-S-753 is between equivalent and <10-fold as potent as amphotericin B. These results are encouraging and warrant further studies on SPA-S-753.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / administration & dosage
  • Amphotericin B / therapeutic use
  • Animals
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / therapeutic use
  • Candida albicans / drug effects
  • Candidiasis / drug therapy*
  • Candidiasis / microbiology
  • Injections, Intravenous
  • Kidney / microbiology
  • Mice
  • Microbial Sensitivity Tests
  • Polyenes / administration & dosage
  • Polyenes / pharmacology*
  • Spleen / microbiology


  • Antifungal Agents
  • Polyenes
  • SPA-S-753
  • partricin
  • Amphotericin B